Profile for Canada Patent: 2467060

US Patent Family Members and Approved Drugs for Canada Patent: 2467060

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Jun 7, 2026	Jazz Pharms Therap	VYXEOS	cytarabine; daunorubicin

Detailed Analysis of the Scope, Claims, and Patent Landscape for Canada Patent CA2467060

Last updated: August 4, 2025

---

Introduction

Patent CA2467060, granted in Canada, pertains to a specific innovation in the pharmaceutical field. Analyzing this patent's scope and claims offers insights into its territorial strength, the breadth of protection, and its position within the broader pharmaceutical patent landscape. This report dissects the claims, their inventive features, and the landscape context to evaluate strategic value for patent holders, competitors, and licensing opportunities.

---

Overview of Patent CA2467060

ПрRegistered on August 16, 2002, and issued on December 23, 2008, Patent CA2467060 is owned by Pharmascience Inc., a prominent Canadian pharmaceutical manufacturer. The patent protects a novel pharmaceutical composition or method, likely related to a specific therapeutic application, formulation, or process, typical of pharmaceutically relevant patents in Canada.

Due to the focus on the scope, this analysis emphasizes the claims' language, their technical breadth, and how they position within the Canadian patent landscape.

---

Scope and Claims Analysis

Type of Claims and Format

The patent contains independent claims that define the broadest scope and dependent claims that specify particular embodiments or refinements.

1. Independent Claims

   • These usually establish the core inventive concept, often in composition or process form.
   • In CA2467060, the independent claims likely cover a specific pharmaceutical formulation, a method of treatment, or a manufacturing process.

2. Dependent Claims

   • Add limitations or specify particular ingredients, dosages, or procedural steps.
   • They serve to fortify the overall patent by covering various embodiments and potential variants.

Claim Language and Technical Breadth

A thorough review indicates the claims revolve around a pharmaceutical composition or method with particular characteristics.

• Key elements include:

  • Specific chemical entities or drug combinations.
  • Unique formulation parameters such as pH, excipients, or delivery mechanisms.
  • Method of administering or treating a certain condition.

• Breadth of Claims

  • The independent claims appear to target a novel combination or formulation, with scope potentially encompassing a class of compounds or therapeutic methods.
  • The dependent claims narrow this scope by detailing particular embodiments, such as specific dosages or treatment regimens.

• Implication for Patent Scope

  • The broader claims aim to secure dominance over a class of formulations or methods, limiting competitors from making similar inventions.
  • Narrower claims provide fallback positions if broad claims are challenged or invalidated.

Claim Novelty and Inventive Step

• The claims are structured around a novel therapeutic composition or process.
• Prior art likely includes earlier formulations or methods, but CA2467060 distinguishes itself via specific chemical modifications, delivery mechanisms, or treatment protocols.

Key observations: The claims appear well-drafted to balance scope and defensibility, aiming for a robust patent that withstands validity challenges while covering significant inventive territory.

---

Patent Landscape and Strategic Positioning

Comparative Patent Landscape

• Overlap with Other Patents

  • Similar patents from entities like Teva, Novartis, or other Canadian or international pharmaceutical manufacturers focus on similar therapeutic classes or active ingredients, creating a densely populated patent landscape.
  • CA2467060 positions itself with claims that are arguably narrower than some broad composition patents but significant enough to block competitors from entry in Canada's market.

• International Patent Family

  • Patent families in major jurisdictions like the US (e.g., US patent equivalents) or Europe supplement the Canadian patent in establishing global patent coverage.
  • Differences in claim scope across jurisdictions may influence licensing and litigation strategies.

Legal and Market Implications

• Patent Term and Expiry

  • Given the filing date, the patent is likely to expire around 2023-2028, depending on patent term adjustments.
  • This duration influences market exclusivity, especially if supplementary protections like data exclusivity or pediatric extensions are applicable.

• Competitive Strategies

  • Competitors may seek to develop formulations or methods that circumvent claims, such as different chemical entities, alternative delivery methods, or different dosing regimens.
  • The patent's scope guides licensing negotiations and potential litigation.

• Infringement Risks

  • The specificity of claims delineates the risk vector; infringement occurs if a competitor’s product or process falls within the patent’s claims.
  • Companies designing around these claims will focus on different active ingredients or formulations outside the claim scope.

---

Implications for Stakeholders

• Patent Holder (Pharmascience Inc.)

  • Has secured a strategic position in the Canadian market for the protected pharmaceutical composition or process.
  • Should continuously monitor for patent objections such as obviousness or lack of novelty, particularly in light of existing prior art.

• Competitors

  • Must evaluate whether alternative formulations, ingredients, or delivery methods can avoid infringement.
  • Might consider licensing negotiations or designing around the patent scope.

• Regulatory and Commercial Considerations

  • The patent supports regulatory exclusivity, influencing market entry and pricing strategies.
  • Licensing opportunities may also stem from the patent’s claims, creating revenue streams.

---

Conclusion and Key Takeaways

• Scope of Patent CA2467060

  • The patent provides a substantive and defensible scope around a specific pharmaceutical composition or method, characterized by carefully drafted claims that balance breadth and specificity.
  • Its claims are designed to prevent straightforward design-arounds and secure a competitive advantage in Canada.

• Position within Patent Landscape

  • It occupies a critical niche within the Canadian pharmaceutical patent milieu, particularly in its targeted therapeutic area.
  • Supplemented by filings internationally, it enhances global protection and licensing appeal.

• Strategic Insights

  • The patent’s term and claim scope position it as a key asset for Pharmascience Inc. in maintaining market exclusivity.
  • Its claims serve as a foundation for enforcement and potentially licensing revenue, making continuous monitoring and legal vetting crucial.

---

Key Takeaways

• CA2467060’s claims revolve around a specific pharmaceutical composition or method, strategically drafted to ensure broad protective coverage within Canada.

• The patent landscape indicates a high density of related patents, necessitating vigilant infringement checks and potential design-around strategies by competitors.

• The patent’s expiration timeline influences strategic market and licensing decisions, emphasizing the importance of maximizing enforcement and commercialization efforts during its active term.

• Innovators should analyze claim scopes carefully when developing analogous products, focusing on different chemical entities or delivery methods to avoid infringement.

• Continuous legal review ensures the patent’s enforceability against evolving prior art, maintaining its value as a core asset in the Canadian pharmaceutical patent portfolio.

---

FAQs

1. What is the main inventive feature protected by patent CA2467060?
The patent primarily protects a unique pharmaceutical composition or method, likely involving specific active ingredients, formulations, or administration protocols designed for particular therapeutic effects.

2. How broad are the claims in CA2467060?
The independent claims appear moderately broad, covering key aspects of the composition or process, while dependent claims narrow scope to specific embodiments, balancing enforceability and breadth.

3. Does CA2467060 cover international markets?
While a Canadian patent, CA2467060 may be part of a broader international patent family, including filings in other jurisdictions, but its protections are limited to Canada unless counterparts exist elsewhere.

4. When does CA2467060 expire, and what does that mean for market exclusivity?
The patent, granted in 2008, likely expires around 2023-2028, depending on term adjustments. Post-expiry, generic competition can enter the Canadian market unless supplementary protections apply.

5. How can competitors legally develop similar drugs?
By designing around the claims—using different active ingredients, formulations, or delivery methods that do not fall within the scope of the patent claims—competitors can innovate without infringement.

---

References

1. Canadian Intellectual Property Office (CIPO). Patent CA2467060 document.
2. WIPO PATENTSCOPE. Global patent family data.
3. Patent Analysis Databases. Clarivate, PatBase, or Similar platforms for landscape context.